2-butoxy-9-[4-fluoro-3-methoxycarbonylmethylbenzyl]-8-hydroxyadenine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-butoxy-9-[4-fluoro-3-methoxycarbonylmethylbenzyl]-8-hydroxyadenine
• 英文别名: methyl 2-[5-[(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)methyl]-2-fluorophenyl]acetate
• 化学式: C₁₉H₂₂FN₅O₄
• 分子量: 403.413
• InChiKey: LCHBDKCICFGKNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  甲醇 、 {5-[(6-amino-8-bromo-2-butoxy-9H-purin-9-yl)methyl]-2-fluorophenyl}acetonitrile 在 sodium hydroxide 、 硫酸 作用下， 以 甲醇 为溶剂， 反应 8.0h， 以321 mg的产率得到2-butoxy-9-[4-fluoro-3-methoxycarbonylmethylbenzyl]-8-hydroxyadenine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept

  摘要：

  Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2)2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.

  DOI：

  10.1021/jm100070n

文献信息

• 8-Oxoadenine Compound
  申请人：Ogita Haruhisa

  公开号：US20070225303A1

  公开（公告）日：2007-09-27

  An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1/Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral diseases and cancers, which is represented by the following formula (1): wherein A is a group of a formula represented by the formula (2): wherein R 2 is a substituted or unsubstituted alkyl group and so on, R 3 is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0˜2, X 1 is oxygen atom, Z is straight or branched chain alkylene, and R 1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.

  一种8-氧腺嘌呤化合物，可用作免疫调节剂，对Th1 / Th2具有特定活性，特别是用于过敏性疾病，病毒性疾病和癌症的局部应用的预防和治疗剂，其化学式（1）如下：其中A是由式（2）表示的式的基团：其中R2是取代或未取代的烷基基团等，R3是氢原子或烷基基团，R是卤素原子等，n为0〜2，X1为氧原子，Z为直链或支链烷基，R1为烷基基团，可选地由羟基基团，烷氧基基团，烷氧羰基基团等取代，或其药学上可接受的盐。
• Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept
  作者：Ayumu Kurimoto、Kazuki Hashimoto、Tomoaki Nakamura、Kei Norimura、Haruhisa Ogita、Haruo Takaku、Roger Bonnert、Tom McInally、Hiroki Wada、Yoshiaki Isobe

  DOI：10.1021/jm100070n

  日期：2010.4.8

  Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2)2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.